PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27978526-12	2016	The effect of bexarotene on annexin-V-binding was significantly blunted by removal of extracellular Ca2+ and by addition of D4476 (10 microM), but not by addition of staurosporine (1 microM), SB203580 (2 microM), or zVAD (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	124-129	annexin A5	Homo sapiens	28-37
34216174-5	2021	We found that down-regulation of Csnk1a1 or inhibition by D4476, a Csnk1a1 inhibitor, reduced GBM cell proliferation efficiently in both Tp53 wild-type and Tp53-mutant GBM cells.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	58-63	casein kinase 1 alpha 1	Homo sapiens	67-74
33861751-10	2021	The CK1 inhibitor, D4476, partly mimicked the CSNK1G2 knockdown effect in ER+ breast cancer cells, but with a broader repression ranging from PI3K/AKT/mTOR/S6K to ERK signaling.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	19-24	casein kinase 1 gamma 2	Homo sapiens	46-53
33861751-10	2021	The CK1 inhibitor, D4476, partly mimicked the CSNK1G2 knockdown effect in ER+ breast cancer cells, but with a broader repression ranging from PI3K/AKT/mTOR/S6K to ERK signaling.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	19-24	AKT serine/threonine kinase 1	Homo sapiens	147-150
33861751-10	2021	The CK1 inhibitor, D4476, partly mimicked the CSNK1G2 knockdown effect in ER+ breast cancer cells, but with a broader repression ranging from PI3K/AKT/mTOR/S6K to ERK signaling.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	19-24	mechanistic target of rapamycin kinase	Homo sapiens	151-155
33861751-10	2021	The CK1 inhibitor, D4476, partly mimicked the CSNK1G2 knockdown effect in ER+ breast cancer cells, but with a broader repression ranging from PI3K/AKT/mTOR/S6K to ERK signaling.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	19-24	ribosomal protein S6 kinase B1	Homo sapiens	156-159
33861751-10	2021	The CK1 inhibitor, D4476, partly mimicked the CSNK1G2 knockdown effect in ER+ breast cancer cells, but with a broader repression ranging from PI3K/AKT/mTOR/S6K to ERK signaling.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	19-24	mitogen-activated protein kinase 1	Homo sapiens	163-166
33635146-8	2021	The results also showed that D4476 significantly reduced the AKT/phospho-beta-catenin (S552) axis concomitantly with autophagy flux inhibition in RAS-mutated CRC cells.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	29-34	AKT serine/threonine kinase 1	Homo sapiens	61-64
33635146-8	2021	The results also showed that D4476 significantly reduced the AKT/phospho-beta-catenin (S552) axis concomitantly with autophagy flux inhibition in RAS-mutated CRC cells.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	29-34	catenin beta 1	Homo sapiens	73-85
30686098-8	2019	Importantly, we provide in vitro and in vivo evidence that UVRAG ubiquitination at lysine residues 517 and 559 or prevention of Ser522 phosphorylation by D4476, a CSNK1A1 inhibitor, enhances the lysosomal degradation of EGFR, which significantly inhibits hepatocellular carcinoma (HCC) growth.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	154-159	UV radiation resistance associated	Homo sapiens	59-64
30686098-8	2019	Importantly, we provide in vitro and in vivo evidence that UVRAG ubiquitination at lysine residues 517 and 559 or prevention of Ser522 phosphorylation by D4476, a CSNK1A1 inhibitor, enhances the lysosomal degradation of EGFR, which significantly inhibits hepatocellular carcinoma (HCC) growth.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	154-159	casein kinase 1 alpha 1	Homo sapiens	163-170
30686098-8	2019	Importantly, we provide in vitro and in vivo evidence that UVRAG ubiquitination at lysine residues 517 and 559 or prevention of Ser522 phosphorylation by D4476, a CSNK1A1 inhibitor, enhances the lysosomal degradation of EGFR, which significantly inhibits hepatocellular carcinoma (HCC) growth.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	154-159	epidermal growth factor receptor	Homo sapiens	220-224
28535537-10	2017	The effect of exemestane (40 microg/ml) on annexin-V-binding was significantly blunted by antioxidant N-acetylcysteine (1mM), but was not significantly modified by removal or increase of extracellular Ca2+, by p38 kinase inhibitor SB203580 (2 microM), casein kinase inhibitor D4476 (10 microM) and caspase inhibitor zVAD (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	276-281	annexin A5	Homo sapiens	43-52
27960155-8	2016	The effect of ceritinib on annexin-V-binding was significantly blunted but not abolished by removal of extracellular Ca2+, by the kinase inhibitors staurosporine (1 microM), SB203580 (2 microM) and D4476 (10 microM), as well as by caspase inhibitor zVAD (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	198-203	annexin A5	Homo sapiens	27-36
35219693-6	2022	We then confirmed the effect of D4476 on the interaction between Beclin 1 and B-cell lymphoma-2 (Bcl-2) through immunoprecipitation with an anti-Bcl-2 antibody.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	32-37	beclin 1	Homo sapiens	65-73
35219693-6	2022	We then confirmed the effect of D4476 on the interaction between Beclin 1 and B-cell lymphoma-2 (Bcl-2) through immunoprecipitation with an anti-Bcl-2 antibody.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	32-37	BCL2 apoptosis regulator	Homo sapiens	78-95
35219693-6	2022	We then confirmed the effect of D4476 on the interaction between Beclin 1 and B-cell lymphoma-2 (Bcl-2) through immunoprecipitation with an anti-Bcl-2 antibody.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	32-37	BCL2 apoptosis regulator	Homo sapiens	96-102
35219693-6	2022	We then confirmed the effect of D4476 on the interaction between Beclin 1 and B-cell lymphoma-2 (Bcl-2) through immunoprecipitation with an anti-Bcl-2 antibody.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	32-37	BCL2 apoptosis regulator	Homo sapiens	145-150
35219693-9	2022	However, D4476 alleviated CQ-induced effects by rescuing ARPE-19 cells from CQ-induced toxicity by modulating the association between Beclin 1 and Bcl-2.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	9-14	beclin 1	Homo sapiens	134-142
35219693-9	2022	However, D4476 alleviated CQ-induced effects by rescuing ARPE-19 cells from CQ-induced toxicity by modulating the association between Beclin 1 and Bcl-2.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	9-14	BCL2 apoptosis regulator	Homo sapiens	147-152
33443517-12	2021	In another way, eugenol was proven to significantly enhance the degradation of beta-catenin when treated with the CK1alpha inhibitor D4476 in vitro by Western blot.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	133-138	catenin (cadherin associated protein), beta 1	Mus musculus	79-91
32901886-9	2020	CK1alpha interacted with murine double minute 2 (MDM2) and p53, and CK1alpha inhibitor D4476 significantly upregulated p53 and phosphorylated 5" AMP-activated protein kinase (AMPK), and substantially inhibited the phosphorylation of mammalian target of rapamycin (mTOR).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	87-92	transformation related protein 53, pseudogene	Mus musculus	119-122
32901886-9	2020	CK1alpha interacted with murine double minute 2 (MDM2) and p53, and CK1alpha inhibitor D4476 significantly upregulated p53 and phosphorylated 5" AMP-activated protein kinase (AMPK), and substantially inhibited the phosphorylation of mammalian target of rapamycin (mTOR).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	87-92	mechanistic target of rapamycin kinase	Homo sapiens	233-262
32901886-9	2020	CK1alpha interacted with murine double minute 2 (MDM2) and p53, and CK1alpha inhibitor D4476 significantly upregulated p53 and phosphorylated 5" AMP-activated protein kinase (AMPK), and substantially inhibited the phosphorylation of mammalian target of rapamycin (mTOR).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	87-92	mechanistic target of rapamycin kinase	Homo sapiens	264-268
28793293-12	2017	The effect of temsirolimus on annexin-V-binding was significantly blunted but not abolished by removal of extracellular Ca2+ and by addition of staurosporine (1 microM) or chelerythrine (10 microM) but not significantly modified by addition of SB203580 (2 microM), D4476 (10 microM), or zVAD (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	265-270	annexin A5	Homo sapiens	30-39
27197532-13	2016	Moreover, the effect of Anidulafungin on annexin-V-binding was not paralleled by significant increase of ceramide abundance and was not significantly blunted by PKC inhibitor staurosporine (1 microM), casein kinase 1alpha inhibitor D4476 (10 microM) or pancaspase inhibitor zVAD (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	232-237	annexin A5	Homo sapiens	41-50
27513568-10	2016	The effect of caspofungin on annexin-V-binding was, however, significantly blunted in the presence of casein kinase inhibitor D4476 (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	126-131	annexin A5	Homo sapiens	29-38
27395049-10	2016	Instead, the effect of Sclareol on annexin-V-binding was significantly blunted in the presence of p38 kinase inhibitor skepinone (2 microM) and in the presence of casein kinase 1alpha inhibitor D4476 (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	194-199	annexin A5	Homo sapiens	35-44
27442249-10	2016	The effect of dolutegravir on annexin-V-binding was significantly blunted by removal of extracellular Ca2+, but was not significantly modified by protein kinase C inhibitor staurosporine (1 microM), p38 kinase inhibitor SB203580 (2 microM), casein kinase inhibitor D4476 (10 microM) or pancaspase inhibitor zVAD (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	265-270	annexin A5	Homo sapiens	30-39
25503443-7	2015	CKI inhibition by small molecule D4476 could abrogate TGF-beta-induced FoxO/Smad activation, reverse Bim up-regulation, and block the sequential apoptosis.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	33-38	choline kinase alpha	Homo sapiens	0-3
27855413-8	2016	The effect of Calyculin A on annexin-V-binding was significantly blunted by removal of extracellular Ca2+, by staurosorine (1 microM), SB203580 (2 microM), D4476 (10 microM), and zVAD (10 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	156-161	annexin A5	Homo sapiens	29-38
25503443-7	2015	CKI inhibition by small molecule D4476 could abrogate TGF-beta-induced FoxO/Smad activation, reverse Bim up-regulation, and block the sequential apoptosis.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	33-38	transforming growth factor beta 1	Homo sapiens	54-62
19759023-5	2009	Depletion of CK1 using small interfering RNA or inhibition of CK1 using the kinase inhibitor (D4476) activated p53 and destabilized E2F-1, indicating that steady-state levels of these proteins are controlled by CK1.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	94-99	transformation related protein 53, pseudogene	Mus musculus	111-114
26699137-10	2015	The effect of efavirenz on annexin-V-binding was further significantly blunted by p38 kinase inhibitor SB203580 (2 microM) and casein kinase 1alpha inhibitor D4476 (10 microM), but not by cyclooxygenase inhibitor aspirin (50 microM).	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	158-163	annexin A5	Homo sapiens	27-36
21084295-9	2011	Mutation of eIF6 at the phosphorylatable Ser-174 and Ser-175 to alanine or treatment of cells with the CK1 inhibitor, D4476 inhibits nuclear export of eIF6 and results in nuclear accumulation of eIF6.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	118-123	eukaryotic translation initiation factor 6	Homo sapiens	12-16
21084295-9	2011	Mutation of eIF6 at the phosphorylatable Ser-174 and Ser-175 to alanine or treatment of cells with the CK1 inhibitor, D4476 inhibits nuclear export of eIF6 and results in nuclear accumulation of eIF6.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	118-123	eukaryotic translation initiation factor 6	Homo sapiens	151-155
21084295-9	2011	Mutation of eIF6 at the phosphorylatable Ser-174 and Ser-175 to alanine or treatment of cells with the CK1 inhibitor, D4476 inhibits nuclear export of eIF6 and results in nuclear accumulation of eIF6.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	118-123	eukaryotic translation initiation factor 6	Homo sapiens	151-155
18669630-9	2008	Low levels of the CK1 inhibitor D4476 selectively inhibited HHV-6B-induced Ser20 site phosphorylation of p53.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	32-37	transformation related protein 53, pseudogene	Mus musculus	105-108
14710188-0	2004	D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a.	4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide	0-5	forkhead box O1	Rattus norvegicus	111-117